July 22, 2024: NCHR’s letter for the record for the House hearing: “The Fiscal Year 2025 Consumer Product Safety Commission Budget” describes the accomplishments of the CPSC and urges Congress to support CPSC’s life-saving work evaluating consumer products, especially those for children, in order to keep all of us safe.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Patient, Consumer, and Public Health Coalition Public Comment to CMS on Transcatheter Tricuspid Valve Replacement Coverage
July 19, 2024: FDA approval of TTVR was premature and the data are inadequate to support the safety and effectiveness of TTVR for the Medicare population. The Patient, Consumer, and Public Health Coalition urges CMS to conduct a thorough MEDCAC review prior to making a coverage decision.
Read More »NCHR Signed On to Letter Urging Greater Appropriations for the Consumer Product Safety Commission
NCHR and other non-profit organizations sent a letter urging increased FY 2025 appropriations for the Consumer Product Safety Commission. CPSC funding should not be subject to cuts or restrictions that would further undermine its ability to protect the public from hazardous consumer products.
Read More »Testimony of Dr. Diana Zuckerman at the Tobacco Products Scientific Advisory Committee Meeting on General Snus
June 26, 2024: NCHR testified at the FDA Advisory Committee about the problems with safety data for General Snus smokeless tobacco and questioned whether they deserve to be labeled as safer than cigarettes.
Read More »NCHR Testimony at the FDA Listening Session on Advisory Committee Meetings
June 13, 2024: NCHR testified at the FDA listening session on Advisory Committee reform. We expressed concerns with the miscategorization of Consumer Representatives on AdComs and the ability of individuals with prior financial ties to industry to serve on these committees.
Read More »